表紙
市場調查報告書

軸性脊椎關節炎 (axSpA):亞太地區流行病學的預測

Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028

出版商 GlobalData 商品編碼 919453
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
軸性脊椎關節炎 (axSpA):亞太地區流行病學的預測 Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028
出版日期: 2020年02月28日內容資訊: 英文 150 Pages
簡介

亞太地區的主要國家,軸性脊椎關節炎 (axSpA)的已受診患病人數,2018年是610萬人,預測2028年是800萬人,以年率3.23%的速度增加。在各國2018年的已受診患病人數中,中國 (都市區) 是310萬人,印度280萬人,澳洲8萬人。人口增加和高齡化的發展等,促進患病人數的增加。

本報告提供亞太地區的主要5個國家 (澳洲,中國 (都市區)印度,韓國,日本) 中,體軸性脊椎關節炎 (axSpA)的發病情形與今後預測相關分析,疾病的特徵,及目前患病者的發病情形,今後10年的患病數量、市場規模預測 (基本/替代性方案),各疾病類型、各特性詳細趨勢等資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 軸性脊椎關節炎 (axSpA):摘要整理

  • 相關分析
  • 出版預定的相關分析

第3章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • 過去的世界的趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法:僵直性脊椎炎 (AS)的場合 - 基本的方案
    • 預測的前提條件與手法:非X光線性軸性脊椎關節炎 (Nr-AxSpA)的場合 - 基本的方案
    • 預測的前提條件與手法:僵直性脊椎炎 (AS)的場合 - 替代的方案
    • 預測的前提條件與手法:非X光線性軸性脊椎關節炎 (Nr-AxSpA)的場合 - 替代的方案
    • 如果預測的前提條件與手法:確診AS患者裡面,有HLA-B27陽性反應的關聯性
  • ) - 基本方案AS/Nr-AsSpA的流行病學的預測 (今後11年份
    • AS的已受診患病人數
    • Nr-AxSpA的已受診患病人數
  • AS/Nr-AsSpA的流行病學的預測 (今後11年份) - 替代性方案
    • AS的已受診患病人數
    • AS的已受診患病人數:各年齡
    • AS的已受診患病人數:男女
    • AS的已受診患病人數:HLA-B27陽性的有無
    • Nr-AxSpA的已受診患病人數
    • Nr-AxSpA的已受診患病人數:各年齡
    • Nr-AxSpA的已受診患病人數:男女
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC184PIDR

The diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) are expected to increase from 6.1 million cases in 2018 to 8.0 million cases in 2028, at an annual growth rate (AGR) of 3.23% across the five growth markets (5GM: Australia, China [urban], India, South Korea and Japan) in the Asia-Pacific (APAC) region.

Axial Spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Axial Spondyloarthritis (AxSpA) usually starts in the third decade of the life, and can have a major impact on patient health-related quality of life and work productivity.

Axial Spondyloarthritis (AxSpA) is an insidious disease and difficult to diagnose. Diagnosis is aided by family history, clinical examination, C-reactive protein (CRP), HLA-B27 testing and radiographic imaging. Diagnoses of Axial Spondyloarthritis (AxSpA) patients have an average delay of eight years from the onset of symptoms.

Of the 5GM (Australia, China [urban], India, South Korea and Japan), China (urban) is expected to have the highest number of diagnosed prevalent cases, increasing from 3.1 million cases in 2018 to 4.1 million cases in 2028. There were 2.8 million cases in India while Australia had 0.08 million diagnosed prevalent cases in 2018. The major drivers for the upward trend in the diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) in the 5GM (Australia, China [urban], India, South Korea and Japan) over the next decade is partly attributable to aging population combined with the increasing trend in the prevalence of the condition.

The latest report, "Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028", provides an overview of the risk factors and historical trends for Axial Spondyloarthritis across the 5GM (Australia, China [urban], India, South Korea and Japan) in the ages ≥18 years.

Scope

  • Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the Asia-Pacific axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Asia-Pacific axSpA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Asia-Pacific axSpA therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the Asia-Pacific axSpA therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

  • 2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018-2028
  • 2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
  • 2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
  • 2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
    • 5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
    • 5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
    • 5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario
    • 5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
  • 5.5 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Base Scenario
    • 5.5.1 Diagnosed Prevalent Cases of AS
    • 5.5.2 Diagnosed Prevalent Cases of Nr-axSpA
  • 5.6 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Alternative Scenario
    • 5.6.1 Diagnosed Prevalent Cases of AS
    • 5.6.2 Age-Specific Diagnosed Prevalent Cases of AS
    • 5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
    • 5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
    • 5.6.5 Diagnosed Prevalent Cases of Nr-axSpA
    • 5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-axSpA
    • 5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA
  • 5.7 Discussion
    • 5.7.1 Epidemiological Forecast Insight
    • 5.7.2 Limitations of the Analysis
    • 5.7.3 Strengths of the Analysis

6 Disease Management in APAC

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 India
  • 6.3 China
  • 6.4 Australia
  • 6.5 South Korea
  • 6.6 Japan

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment in APAC

10 Current and Future Players in APAC

11 APAC Markets

12 Appendix

List of Tables

  • Table 1: Axial Spondyloarthritis: Key Metrics in the 5GM
  • Table 2: Risk Factors and Comorbidities for AS
  • Table 3: Treatment Guidelines for AxSpA
  • Table 4: Country Profile - India
  • Table 5: Country Profile - China
  • Table 6: Country Profile - Aus

List of Figures

  • Figure 1: Global Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Axial Spondyloarthritis During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of Axial Spondyloarthritis During the Forecast Period
  • Figure 4: Pathogenic Mechanisms of Axial Spondyloarthritis
  • Figure 5: 5GM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ≥18 Years, 2008-2028 - Base Scenario
  • Figure 6: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Base Scenario
  • Figure 7: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
  • Figure 8: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Alternative Scenario
  • Figure 9: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario
  • Figure 10: 5GM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario
  • Figure 11: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
  • Figure 12: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
  • Figure 13: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 14: 5GM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 15: 5GM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥18 Years, N, 2018 - Alternative Scenario
  • Figure 16: 5GM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 17: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 18: 5GM, Age-Specific Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 19: 5GM, Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, N, 2018 - Alternative Scenario
  • Figure 20: Flowchart of the Diagnosis and Management of Axial Spondyloarthritis
  • Figure 21: Unmet Needs and Opportunities in AxSpA
  • Figure 22: Overview of the Development Pipeline for AxSpA
  • Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period
  • Figure 24: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period
  • Figure 25: Analysis of the Company Portfolio Gap in AxSpA in the 5GM, During the Forecast Period
  • Figure 26: APAC (5GM) Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
  • Figure 27: Sales Forecast by Class for Axial Spondyloarthritis in India in 2018 and 2028
  • Figure 28: Sales Forecast by Class for Axial Spondyloarthritis in China in 2018 and 2028
  • Figure 29: Sales Forecast by Class for Axial Spondyloarthritis in Australia in 2018 and 2028
  • Figure 30: Sales Forecast by Class for Axial Spondyloarthritis in South Korea in 2018 and 2028
  • Figure 31: Sales Forecast by Class for Axial Spondyloarthritis in Japan in 2018 and 2028